SCHEMBL30736468

SCHEMBL30736468

Cc1cccc(/C=C/C(=O)c2ccc(O)c(O)c2O)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 1/20 0.67
NR1H4 Q96RI1 2/20 0.60
KDM4E B2RXH2 1/20 0.60
MEN1 O00255 1/20 0.60
ALDH1A1 P00352 1/20 0.60
LMNA P02545 1/20 0.60
POLB P06746 1/20 0.60
MAPT P10636 1/20 0.60
XBP1 P17861 1/20 0.60
ALOX12 P18054 1/20 0.60
RECQL P46063 1/20 0.60
KMT2A Q03164 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
MAOA P21397 2/20 0.55
MAOB P27338 2/20 0.55
NFE2L2 Q16236 1/20 0.54
ABCG2 Q9UNQ0 1/20 0.51
HSP90AA1 P07900 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31436362 1.00 TERT (0.67) TERTNR1H4KDM4EMEN1ALDH1A1
SCHEMBL28273153 1.00 TERT (0.67) TERTNR1H4KDM4EMEN1ALDH1A1
SCHEMBL28488132 1.00 TERT (0.67) TERTNR1H4KDM4EMEN1ALDH1A1
SCHEMBL2541144 0.85 TERT (0.70) TERTNR1H4KDM4EMEN1ALDH1A1
SCHEMBL30736439 0.85 TERT (0.70) TERTNR1H4KDM4EMEN1ALDH1A1
SCHEMBL2541146 0.85 TERT (0.70) TERTNR1H4KDM4EMEN1ALDH1A1
SCHEMBL31436349 0.85 TERT (0.70) TERTNR1H4KDM4EMEN1ALDH1A1
SCHEMBL30736445 0.83 CYP1B1 (0.68) TERTNR1H4ALDH1A1MAOAMAOB
SCHEMBL31436356 0.83 CYP1B1 (0.68) TERTNR1H4ALDH1A1MAOAMAOB
SCHEMBL25265116 0.82 MAOB (0.73) KDM4EMEN1ALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250228795-A1 ESTROGENIC COMPOUNDS AND METHODS OF USE IATERION, INC. 2025-07-17 US disclosed
EP-4561560-A1 ESTROGENIC COMPOUNDS AND METHODS OF USE Iaterion, Inc. (US) 2025-06-04 EP disclosed
CN-119677514-A Estrogenic compounds and methods of use 益特瑞恩公司 2025-03-21 CN disclosed
WO-2024026034-A1 ESTROGENIC COMPOUNDS AND METHODS OF USE IATERION, INC. (US) 2024-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250228795-A1 ESTROGENIC COMPOUNDS AND METHODS OF USE ESR1, ESR2, CYP19A1 TERT 3056/4885NR1H4 54/4885KDM4E 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.